Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 9, Issue 9, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2021-003032
Keywords
macrophages; CD8-positive T lymphocytes; tumor microenvironment; immunotherapy; lymphocytes; tumor-infiltrating
Categories
Funding
- Hope Against Cancer
Ask authors/readers for more resources
Malignant pleural mesothelioma (MPM) is a difficult-to-treat cancer, but recent trials on immune checkpoint blockade (ICB) have shown promising results. While TMB and PD-L1 may not predict ICB response in MPM, understanding the tumor immune microenvironment can lead to improved therapy outcomes.
Malignant pleural mesothelioma (MPM) is an incurable cancer with a dismal prognosis and few effective treatment options. Nonetheless, recent positive phase III trial results for immune checkpoint blockade (ICB) in MPM herald a new dawn in the fight to advance effective treatments for this cancer. Tumor mutation burden (TMB) has been widely reported to predict ICB in other cancers, but MPM is considered a low-TMB tumor. Similarly, tumor programmed death-ligand 1 (PD-L1) expression has not been proven predictive in phase III clinical trials in MPM. Consequently, the precise mechanisms that determine response to immunotherapy in this cancer remain unknown. The present review therefore aimed to synthesize our current understanding of the tumor immune microenvironment in MPM and reflects on how specific cellular features might impact immunotherapy responses or lead to resistance. This approach will inform stratified approaches to therapy and advance immunotherapy combinations in MPM to improve clinical outcomes further.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available